Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03281304 · ClinicalTrials.gov registry record · Phase 4
A Study of Tofacitinib in Patients With Ulcerative Colitis in Stable Remission
A Phase 4 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 4
- Development phase
- 140
- Enrollment target
NCT03281304 is a Phase 4 study that was terminated before completion, run by Pfizer. The registered enrollment target is 140 participants.
The verdict
NCT03281304, a Phase 4 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 140 participants
- Enrollment target
Study Summary
This study is a follow up study for subjects with Ulcerative Colitis (UC) in stable remission designed to evaluate flexible dosing of CP-690,550.
Interventions
- DRUG CP-690,500 5 mg
- DRUG CP-690,550 10 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2017-11-16 |
| Est. Completion | 2022-03-18 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03281304
The ClinicalTrials.gov registry entry for NCT03281304 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which CP-690,500 5 mg is the first listed.
NCT03281304 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03281304 about?
NCT03281304 is a clinical study titled "A Study of Tofacitinib in Patients With Ulcerative Colitis in Stable Remission". This study is a follow up study for subjects with Ulcerative Colitis (UC) in stable remission designed to evaluate flexible dosing of CP-690,550.
What is the current status of trial NCT03281304?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 140 participants. The study started on 2017-11-16. Estimated completion is 2022-03-18.
What interventions are being tested in trial NCT03281304?
The interventions under investigation include: CP-690,500 5 mg (DRUG), CP-690,550 10 mg (DRUG).
Who is sponsoring clinical trial NCT03281304?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.